What UK REACH is for
Understanding the four objectives written into the regulation is not an academic exercise. They are the reasoning HSE applies when it decides whether your dossier is adequate, and they are the standard against which a data waiver or a read-across argument succeeds or fails.
Protecting human health
Workers, professional users, consumers and people exposed indirectly through the environment. This is why the chemical safety report models exposure across the whole lifecycle rather than at the point of manufacture alone.
Protecting the environment
Aquatic, terrestrial and atmospheric compartments, with particular weight on persistence and bioaccumulation. It explains why PBT and vPvB assessment sits separately from ordinary hazard assessment.
Free circulation of substances
A single set of rules for the GB market rather than a patchwork. This objective is why registration is a market access condition — one common standard everyone must meet.
Promoting alternatives to animal testing
Vertebrate testing is a last resort in law, not merely in principle. Non-testing methods are the preferred route where they can carry the argument.
The principle underneath all four
UK REACH reverses the ordinary regulatory burden. It is not for the regulator to prove a substance is unsafe before acting. It is for industry to demonstrate a substance can be used safely before selling it.
This is why "no data, no market" is not a slogan but an operative rule: an absence of information is treated as a reason to keep a substance off the market, not as a neutral fact.
Why objective four is worth money to you
The preference for alternatives to animal testing is a legal position, not a preference. Where a validated non-testing method can satisfy an information requirement, using it is the compliant route — and it is very substantially cheaper than commissioning the study. QSAR, read-across, weight of evidence and exposure-based adaptation exist because the regulation wants them used. How to use them →
How the objectives shape a dossier assessment
When HSE reviews a registration, it is asking whether the file serves these purposes — not whether boxes are ticked. That has practical consequences for how arguments should be written:
- A data waiver succeeds when it shows the endpoint is irrelevant to protecting health or the environment for this substance and these uses. It fails when it only shows the study is expensive.
- A read-across succeeds when the similarity hypothesis explains why the source substance's toxicological behaviour predicts the target's. It fails when it only shows the structures look alike.
- An exposure-based adaptation succeeds when the exposure evidence is real and documented. It fails when it rests on an assumption about downstream use that nobody has confirmed.
- Narrow identified uses look tidy and cause commercial problems, because a customer's real application then falls outside the registration.
The objective that is not in the list
UK REACH is not designed to make chemicals cheap, and it is not designed to protect incumbents. It has a competitiveness dimension — the Alternative Transitional Registration model exists precisely because the cost of rebuilding a GB data pool was judged disproportionate — but cost is a consideration in how the regime is designed, not a defence available to an individual registrant.